Optimum Investment Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Optimum Investment Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-200	Closed	-$22.8K	–	795
2022 Q4	$22.8K	Hold	200	–	–	0.01%	471
2022 Q3	$12K	Hold	200	–	–	0.01%	569
2022 Q2	$16K	Sell	200 -975	-83%	-$92.3K	0.01%	547
2022 Q1	$124K	Buy	+1,175	New	+$115K	0.05%	285
2019 Q2	–	Sell	-800	Closed	-$21K	–	1039
2019 Q1	$21K	Buy	+800	New	+$19K	0.01%	683

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Optimum Investment Advisors's HZNP Position: Q1 2023 in Review

Optimum Investment Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 200 shares — an estimated $22.8K sold.

Optimum Investment Advisors first reported a position in HZNP in Q1 2019 and held it in 5 quarters. The position peaked at $124K in Q1 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Optimum Investment Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Optimum Investment Advisors sold 200 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $22.8K.
Optimum Investment Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2019 and held it in 5 quarters.
Optimum Investment Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $124K in Q1 2022.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Optimum Investment Advisors's 13F filing for Q1 2023, filed 3 May 2023.